Primary tumor response to targeted agents in patients with metastatic renal ... - UroToday PDF Print
UroTodayThe recent development of multiple targeted agents for metastatic renal cell carcinoma (mRCC) has changed the treatment paradigm; hence the benefit and

...

 
Share |
Copyright © 2025 Global Dialysis. All Rights Reserved.